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The present study was undertaken to characterize the eﬀects of Danggui-Shaoyao-San (DSS), a famous traditional Chinese
medicine formula consisting of six herbal medicines, on diabetic nephropathy. Streptozotocin-induced diabetic rats were orally
administrated DSS (2.8 gkg−1 per day) for 12 consecutive weeks. DSS partially decreased the high plasma glucose level in diabetic
rats. Diabetic-dependent alterations in urinary albumin, 24-hour urinary albumin excretion rate, and creatinine clearance as
well as the kidney hypertrophy (kidney weight/body weight ratio) and glomerular mesangial matrix expansion were ameliorated
after 12 weeks of DSS treatment. The increased expression of nuclear factor-κB as well as transforming growth factor-β1 and the
progressive accumulation of type IV collagen in kidney of diabetic rats were also attenuated by DSS. Not only the elevated levels of
advancedglycation endproducts(AGEs)andNε-(carboxymethyl)lysinebutalsothehigherlevels oflipidperoxidationproductsin
kidney of diabetic rats were ameliorated by DSS. Decreased activity of superoxide diamutase and glutathione peroxidase in kidney
of diabetic rats was enhanced by DSS. These data demonstrated that the renoprotective eﬀects of DSS in STZ-diabetic rats not
only were attributable to regulate plasma glucose to attenuate AGEs expression in diabetic glomeruli but also likely reﬂected its
antioxidant activity.
1.Introduction
A dramatic worldwide increase in the number of patients
with diabetes has been reported, and the disease is becoming
a serious social problem. Among diabetic complications,
nephropathy is the most common cause of end-stage renal
disease (ESRD) in developed countries and a major cause
of morbidity and mortality in patients with diabetes [1].
It is characterized by structural abnormalities including
hypertrophy of both glomerular and tubular elements,
increase in the thickness of glomerular basement mem-
branes, and progressive accumulation of extracellular matrix
components [2]. It also results in functional alterations
including the early increase in the glomerular ﬁltration rate
with intraglomerular hypertension, subsequent proteinuria,
systemic hypertension, and eventual loss of renal function
[2]. The development of irreversible renal change in diabetes
mellitus such as glomerulosclerosis and tubulointerstitial
ﬁbrosis results ultimately in ESRD [1]. Measures to prevent
the appearance and progression of diabetic nephropathy
should therefore be instituted as early as possible. Although
adequate control of blood glucose levels may prevent the
development of complications, it is diﬃcult to achieve strict
blood glucose control, leading to a year-by-year increase in
the number of patients with diabetes [3].
Beyond glycaemic control, other metabolic factors have
been shown to be involved in the development of dia-
betic kidney disease, that is, advanced glycation end prod-
ucts(AGEs).Furthermore,anadequatecontrolofhighblood
pressure and treatment of microalbuminuria are major2 Evidence-Based Complementary and Alternative Medicine
therapeutic targets. To achieve adequate blood pressure
control, a combination therapy with diﬀerent classes of
antihypertensive agents is often necessary, especially includ-
ing angiotensin-converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs) [4]. Besides hyper-
glycaemia and high blood pressure, other risk factors have
beenidentiﬁedinthedevelopmentorprogressionofdiabetic
kidney disease, such as hyperlipidaemia and obesity. The
increased lipid peroxidation in the kidney implies the level of
susceptibility to diabetic oxidative stress, leading to diabetic
complications. From this view point, prevention of hyper-
lipidemia and/or lipid peroxidation resulting from oxidative
stress is considered to play a crucial role in protection from
disorders associated with diabetes [5]. Therefore, new drugs
for treatment of diabetic nephropathy based on diﬀerent
mechanisms of action are needed.
Danggui-Shaoyao-San (DSS), also called Toki-
shakuyaku-san or TJ-23, comprising Radix Paeoniae Alba,
Radix Angelica sinensis,R h i z o m aChuanxiong, Poria cocos,
RhizomaAtractylodismacrocephalae,andRhizomaAlismatis,
is a widely used formula of traditional Chinese medicine
(TCM) derived from “Jingui Yaolue”, a medical classic
written by Zhongjing Zhang in the Eastern Han Dynasty.
Identiﬁcation and determination of the major constituents
in traditional Chinese medicinal prescriptions is constantly
being carried. Researchers have much information on
a lot of active fractions and components from DSS
[6]. Monoterpene glycosides, phenolic compounds, and
phthalides are the most representative components of DSS
as far as both the contents and their biological activities are
concerned. Monoterpene glycosides are responsible for the
eﬃcacy of R. Paeoniae Alba. A case in point is albiﬂorin
and paeoniﬂorin, which exhibits analgesia, spasmolysis,
anti-inﬂammation, and anticoagulation activities [7].
Phenolic acids and phthalides in R. Angelica sinensis and
R. Chuanxiong also have vasodilatative, antithrombotic,
antioxidative, anti-inﬂammatory, and muscle relaxant
eﬀects [8]. In addition, atractylenolides from R. Atractylodis
macrocephalae showed gastrointestinal inhibitory, anti-
inﬂammatory, and antioxidative activity [9]. Meanwhile,
cytotoxic, anti-inﬂammatory, and antioxidant activity of
triterpenes in R. Alismatis and Poria cocos has also been
documented[10,11].DSShasbeenusedinChinaasablood-
activating and stasis-eliminating drug to treat gynecological
disorders such as dysmenorrhea, amenorrhea, and infertility
without observation of side eﬀects for thousands of years
[12, 13]. Recent studies show that it also possesses the
capability of treating neural dysfunctions such as senile
dementia, memory loss, and other cognitive disorders; thus
the formula is used as a remedy for Alzheimer’s disease in
Japan [14, 15]. The amelioration of streptozotocin diabetes-
induced renal damage by the herbal formula containing
Poria cocos,R .Alismatis,a n dR .Atractylodis macrocephalae
has been documented [16]. Although so many beneﬁcial
eﬀects have been shown, the possibility of DSS is beneﬁcial
in the treatment of diabetic nephropathy has not been
previously explored.
Diabetes usually can be classiﬁed as type 1 or type
2 on the basis of the patient’s clinical presentation. It is
often stated that type 1 diabetes results from a complex
interplay between varying degrees of genetic susceptibility
and environmental factors. Patients with diabetes mellitus
type 1 present with an extensive risk for microvascular
complications like retinopathy, nephropathy, and peripheral
neuropathy. The natural history of diabetic nephropathy
diﬀersaccordingtothetypeofdiabetesandwhethermicroal-
buminuria is present. If untreated, 80% of people who have
type 1 diabetes and microalbuminuria will progress to overt
nephropathy, whereas only 20–40% of those with type 2
diabetes over a period of 15 years will progress [17]. The
present study was conducted to characterize the eﬃcacy of
DSS on diabetic nephropathy of type 1 diabetes utilizing
streptozotocin-induced diabetic rats (STZ-diabetic rats) as
an animal model.
2. Methods
2.1. Materials. The concentrated powders for DSS (Cat.,
no. 3520), made of 100% pure authentic Chinese herbs of
highest qualities, were produced by Kaiser Pharmaceutical
Co., Ltd. (Tainan, Taiwan) under internationally certiﬁed
Good Manufacturing Practices guidelines. The experienced
botanists and chemists in the supplier use macroscopic
and microscopic examinations as well as thin-layer chro-
matography and high-performance liquid chromatography
identiﬁcation to authenticate the plants, plant parts used,
and processed raw herbs. The reference specimens were
deposited at the herbarium of supplier to permit future
reference and veriﬁcation. DSS is composed of the following
6 raw materials in the dry weight ratio of 3:16:8:4:4:8.
Angelica sinensis (Oliv.) Diels (family: Umbelliferae), Paeonia
lactiﬂora Pall. (family: Ranunculaceae), Ligusticum chuanx-
iong Hort. (family: Umbelliferae), Poria cocos (Schw.) Wolf
(family: Polyporaceae), Atractylodes macrocephala Koidz.
(family: Compositae), and Alisma orientalis (Sam.) Juzep.
(family: Alismaceae). The formula is cooked as a soup,
combining all ingredients at the appropriate amount of
distilled water. Low temperature processing is employed to
slowly concentrate the extracts, protecting, releasing, and
maintainingallessentialingredients.Aqueousextractoftotal
ingredients was concentrated to 3g of dry weight to meet the
ratio of 5:1 in the powder of DSS. Streptozotocin (STZ) and
sodium pentobarbital were purchased from Sigma-Aldrich,
Inc. (Saint Louis, Mo, USA). The diagnostic kits for determi-
nations of glucose (Cat., no. COD12503), cholesterol (Cat.,
no.COD11539), and triglyceride (Cat., no. COD11529) in
plasma were purchased from BioSystem (Barcelona, Spain).
Nephrat II enzyme-linked immunosorbent assay (ELISA) kit
(Cat., no. NR002) was obtained from Exocell, INC. (PA,
PUA). The diagnostic kits for determinations of creatinine
concentration in serum or urine (Cat., no. 221-30), and
kinetic reagent for measurement of blood urea nitrogen
(BUN) (Cat., no. 283-30) were purchased from Diagnos-
tic Chemicals Limited (Conn, USA). Rabbit polyclonal
antinuclear factor (NF)-κB p65 antibody (Cat., no. sc-
109) was purchased from Santa Cruz Biotechnology, Inc.
(SantaCruz,Calif,USA).Rabbitpolyclonalantitransforming
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purchased from Cell Applications, Inc. (Calif, USA). Rabbit
polyclonal antitype IV collagen antibody (Cat., no. ab6586)
was from Abcam plc (Cambridge, UK). Labeled strepta-
vidin biotin reagent and liquid diaminobenzidine (DAB)+
substrate chromogen system were purchased from DAKO
Corporation (Calif, USA). Anti-Nε-(carboxymethyl)lysine
(CML) rat autoantibody ELISA kit (Cat., no. CY-8069) was
from MBL International (Mass, USA). Bioxytech LPO-586
kit was obtained from OXIS International (Portland, USA).
The colorimetric assay kits for measurements of superoxide
dismutase (SOD, Cat., no. 706002), and glutathione perox-
idase (GSH-Px, Cat., no. 703102) activities in plasma were
purchasedfromCaymanChemical(Mich,USA).Theprotein
assay kit was obtained from Bio-Rad Laboratories (Calif,
USA). All analyses were performed in accordance with the
manuals provided by the manufacturers.
2.2. Animal Models. Male Wistar rats, aged 8–10 weeks,
were obtained from the National Laboratory Animal Center
(Taipei, Taiwan). They were maintained in a temperature-
controlled room (25 ± 1◦C )a n dk e p to na1 2 : 1 2l i g h t -
dark cycle (light on at 06:00h) in our animal center. Food
and water were available ad libitum.S T Z - d i a b e t i cr a t sw e r e
prepared by intravenously (i.v.) injecting 60mg/kg STZ into
male Wistar rats. Animals were considered to be diabetic
if they had plasma glucose concentrations of 350mg/dL or
greaterinadditiontopolyuriaandotherdiabeticfeatures.All
studieswerecarriedout2weeksaftertheinjectionofSTZ.All
animal procedures were performed according to the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health as well as the guidelines of the Animal
Welfare Act.
2.3. Treatment Protocols. One-gram powders of DSS were
well dispersed in 5mL of distilled water to have the 100%
solution for treatment. A metabolism coeﬃcient of 6.25
was employed to convert the recommended daily dosage
of DSS at 27g for adult into rats, assuming that average
body weight of an adult is 60kg [18]. Thus, STZ-diabetic
rats daily received oral treatment with DSS at 2.8gkg−1.
Another group of STZ-diabetic rats and nondiabetic rats
received the equivalent volume of distilled water used to
prepare the preparation. All animals were administered once
daily via gastric tube. The standard rat diet and water were
available ad libitum throughout the entire treatment period.
Every four weeks after the treatment, rats were weighed, and
blood samples were collected from a tail vein; meanwhile,
individual rat was placed in metabolic cages (Shineteh
Instruments Co., Ltd., Taipei, Taiwan) to obtain 24-hour
urine collections for measurements of urine creatinine (Cr)
and albumin concentrations. The systolic blood pressure
(SBP) of the tail artery was also measured at monthly
intervals.
Rats were sacriﬁced at the end of the 12-week treatment
when the rats were deeply anaesthetized by sodium pento-
barbital.Kidneysweredissectedandrinsedwithcoldisotonic
saline and then weighed. An index of renal hypertrophy
was estimated by comparing the wet weight of the left
kidney to the body weight. Thereafter, and some kidney
tissues were put at once in liquid nitrogen and stored at
−80◦C for biochemical and enzymatic determinations, some
were ﬁxed in 10% neutralized formalin for histology and
immunohistochemistry.
2.4. Blood Sampling and Analysis. Blood sample of rats were
centrifuged at 2,000gfor 10 minutes at 4◦C, and plasma was
removed and aliquot for the respective analytical determi-
nations. The diagnostic kits for determinations for plasma
levels of glucose (Cat., no. COD12503), cholesterol (Cat.,
no. COD11539), and triglyceride (Cat., no. COD11529)
were purchased from BioSystem (Barcelona, Spain). The
serum creatinine (Cr) concentration was determined by the
commercial assay kit (Cat., no. 221-30) purchased from
Diagnostic Chemicals Limited (Conn, USA). Blood urea
nitrogen (BUN) was determined by kinetic reagent (Diag-
nostic Chemicals Limited, Cat., no. 283-30). All analyses
were performed in accordance with the manuals provided by
the manufacturers.
2.5. Analysis of Urine Parameters. The 24-h urine col-
lected from each diabetic rat and age-matched control
was centrifuged at 2,000g for 10min. Urinary albumin
concentrations were measured by Nephrat II enzyme-
linked immunosorbent assay (ELISA) kit (Cat., no. NR002)
obtained from Exocell, INC. (PA, PUA). The concentration
of Cr in pooled urine samples was determined by the
commercial assay kit (Diagnostic Chemicals Limited, Cat.,
no. 221-30). All analyses were performed in accordance
with the manuals provided by the manufacturers. The 24-h
urinary albumin excretion rate (UAER) was calculated as:
UAER (μg2 4 h −1) = urinary albumin (μgmL −1) × 24-h
urine volume (mL). Cr clearance (Ccr) was calculated using
the following equation: Ccr (mLmin−1 kg−1) = [urinary Cr
(mgdL−1) × urinary volume (mL)/serum Cr (mg dL−1)] ×
[1000/body weight (g)] × [1/1440 (min)].
2.6. Blood Pressure Measurement. The SBP of the tail
artery was measured by noninvasive blood pressure system
(MODEL BP-6, Diagnostic & Research Instruments Co.,
Ltd., Taoyuan, Taiwan). The measurements for SBP were
recorded in quadruplicate for each rat, and the average blood
pressure was calculated.
2.7. Renal Histological Analysis. For morphometric analysis,
thekidneywasremovedandembeddedinparaﬃntoprepare
4-μmtissueslices.Thetissuesliceswerestainedwithperiodic
acid-Schiﬀ (PAS). The mesangial expansion index (MEI) was
scoredinfourlevelsfrom0to3,withtheindexscoresdeﬁned
as follows [19]: 0, normal glomeruli; 1, matrix expansion
occurred in up to 50% of a glomerulus; 2, matrix expansion
occurred in 50 to 75% of a glomerulus; 3, matrix expansion
occurredin75to100%ofaglomerulus.Scoreswereassigned
for at least 30 glomeruli from kidney slices from each animal,
and the means were calculated. Each slide was scored by a
pathologist who was unaware of the experimental details.
2.8. Immunohistochemistry Staining. For immunohisto-
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buﬀered formalin, casted in paraﬃn, sliced into 4μm
sections, and placed onto microscope slides. After removal
of the paraﬃn by xylene and dehydration by graded alcohol,
slides were immersed into distilled water. Kidney sections
were then transferred into a 10mmolL−1 citrate buﬀer
s o l u t i o na n dh e a t e da t8 0 ◦C for 5 minutes for antigen
retrieval. After washing, 3.0% peroxide was applied for 20
minutes to block the activity of endogenous peroxidase.
To avoid nonspeciﬁc staining, slides were incubated with
normal goat serum at room temperature for 20 minutes.
The sections were then incubated in blocking solution
( 5 %B S A )f o r1h o u ra tr o o mt e m p e r a t u r e ,f o l l o w e db y
treatment with anti-NF-κB p65 antibody (1:200), anti-
TGF-β1 antibody (1:200), or antitype IV collagen antibody
(1:500), where indicated overnight at 4◦C. Negative
control sections were stained under the identical conditions
by substituting the primary antibody with equivalent
concentrations of normal rabbit IgG. After washing with
phosphate buﬀered saline, the slides were incubated with
the labeled streptavidin biotin reagent, following the
manufacturer’s instructions. Immunoreactive products were
made visible by DAB reaction. Sections were counterstained
with haematoxylin for 15 seconds. Brownish yellow granular
or linear deposits were interpreted as positive areas. To
evaluate the immunostaining, a total of more than 30
randomly chosen glomeruli per rat was coded and graded
in a blind manner. Each score reﬂects changes in the extent
rather than the intensity of staining and depends on the
percentage of positive glomeruli. The degree of TGF-β1 and
type IV collagen expression in four rats from each group
was graded as follows: 0, absent or less than 25% staining;
1, 25–50% positive staining; 2, 50–75% positive staining; 3,
more than 75% positive staining [20].
2.9. Renal Advanced Glycation End Products (AGEs) Level.
The renal AGE level was determined according to previous
method with slight modiﬁcations [21]. Minced kidney tissue
was delipidated with chloroform and methanol (2:1, v/v)
overnight. After washing, the tissue was homogenized in
0.1NNaOH,followedbycentrifugationat8,000gfor15min
at 4◦C. The amounts of AGEs in these alkali-soluble samples
were determined by measuring the ﬂuorescence at an
emission wavelength of 440nm and an excitation wavelength
of 370nm using a ﬂuorescence spectrophotometer (F-4500,
Hitachi, Japan). A native bovine serum albumin (BSA)
preparation (1mgmL−1 of 0.1N NaOH) was used as a
standard, and its ﬂuorescence intensity was deﬁned as one
unit of ﬂuorescence. The ﬂuorescence values of samples
were measured at a protein concentration of 1mgmL−1 and
expressed in AU compared with a native BSA preparation.
2.10. Assessment of Renal Nε-(carboxymethyl)lysine
(CML). The kidney was homogenized in ice-cold buﬀer
(0.1mmolL−1 KH2PO4/K2HPO4,p H7 . 0 ,p l u s2 9 . 2 m g
ethylenediaminetetraacetic acid in 100mL of distilled water
and 10mg digitonin in 100mL of distilled water, ﬁnal
volume, 2,000mL) to produce a homogenate. The kidney
homogenates were then centrifuged at 10,000g for 10min
at 4◦C. Then, the supernatant was tested for CML using
the anti-CML rat autoantibody ELISA kit which employs
the semiquantitative enzyme immunoassay technique. The
absorbance of the resulting yellow product is measured at
450nm.
2.11.EstimationofRenalLipidPeroxidationProducts. Kidney
was homogenated as described above and centrifuged at
10,000g for 10min at 4◦C. The supernatant was collected
and immediately tested for lipid peroxidation products using
the Bioxytech LPO-586 kit. The kit uses a chromatogenic
reagent which reacts with the lipid peroxidation prod-
ucts malondialdehyde and 4-hydroxyalkenals at 45 ± 1◦C,
yielding a stable chromophore with maximum absorbance
586nm.
2.12. Measurement of Renal Antioxidant Enzyme Activity.
Total SOD (E.C.: 1.15.1.1) activity evaluated in kidney
homogenates was determined by commercial kit for mea-
suring its ability to inhibit the photochemical reduction of
tetrazolium salt in absorbance at 450nm. The activity assay
for GSH-Px (E.C.: 1.11.1.9) determined by commercial kit
was based on the oxidation of NADPH to NAD+, catalyzed
by a limiting concentration of glutathione reductase, with
maximum absorbance at 340nm. Data are expressed as units
(U) per mg of protein as compared with the standard. The
total protein in each tissue lysate was measured using Bio-
Rad protein assay kit.
2.13. Statistical Analysis. Data are expressed as the mean ±
SD for each group of animals at the number (n) indicated in
tables. Statistical diﬀerences among groups were determined
by using two-way repeated measures ANOVA. The Dunnett
range post hoc comparisons were used to determine the
source of signiﬁcant diﬀerences where appropriate. A P value
<0.05 was considered statistically signiﬁcant.
3. Results
3.1. General Characteristics of Rats. At the beginning of the
treatment, the plasma glucose was signiﬁcantly increased in
vehicle-treatedSTZ-diabeticratsascomparedtonondiabetic
group; these changes were more marked at the 12th week
following diabetes induction (Table 1). Although the plasma
glucose in STZ-diabetic rats receiving DSS treatment for 4
weeks was somewhat lower than the corresponding values
for vehicle-treated group, these diﬀerences did not achieve
statisticalsigniﬁcance(Table1).Theplasmaglucoselowering
eﬀect was more markedly when STZ-diabetic rats receiving
D S St r e a t m e n tf o r1 2w e e k s( T a b l e1). The DSS-induced
plasma glucose lowering eﬀect in STZ-diabetic rats was
persisted to the end of the treatment. DSS also abridged the
weightgainlossindiabeticratsattheendoftheexperimental
period (Table 1).
In addition, the plasma levels of cholesterol and triglyc-
eride were markedly higher in vehicle-treated STZ-diabetic
rats than those in nondiabetic group (Table 1). Plasma levels
of cholesterol and triglyceride in STZ-diabetic rats were
slightly lower by DSS at all time points throughout the studyEvidence-Based Complementary and Alternative Medicine 5
Table 1: Changes of the body weights, plasma parameters, and SBP in STZ-diabetic rats receiving DSS treatment.
Period
(week) Body weight (g) Plasma glucose
(mgdL−1)
Plasma cholesterol
(mgdL−1)
Plasma triglyceride
(mgdL−1) SBP (mmHg)
Nondiabetic rats
Vehicle
0 193.3 ± 11.2 92.8 ± 2.4d 68.5 ± 4.1c 94.2 ± 7.6d 87.3 ± 3.1c
4th 223.8 ± 10.4c 93.6 ± 3.4d 69.4 ± 3.8c 100.4 ± 6.8d 89.4 ± 2.9c
8th 247.6 ± 13.1c 95.4 ± 2.7d 70.2 ± 3.4c 98.4 ± 8.2d 90.3 ± 3.7c
12th 262.6 ± 12.3c 96.8 ± 3.1d 71.3 ± 3.6c 98.6 ± 6.4d 92.6 ± 3.4c
STZ-diabetic rats
Vehicle
0 183.7 ± 10.5 408.6 ± 3.7b 110.9 ± 4.2a 338.4 ± 8.3b 115.5 ± 4.4a
4th 176.2 ± 9.5a 412.5 ± 3.8b 114.6 ± 3.9a 345.6 ± 9.2b 124.6 ± 3.7a
8th 168.3 ± 8.9a 418.7 ± 4.1b 118.1 ± 4.1a 349.2 ±12.4b 129.8 ± 3.9a
12th 160.5 ± 11.4a 423.2 ± 4.4b 118.4 ± 4.7a 353.5 ± 10.1b 134.5 ± 3.6a
DSS
(2.8gkg−1 per day)
0 184.1 ± 9.7 409.6 ± 4.1b 112.3 ± 4.8a 339.2 ± 8.1b 115.1 ± 4.3a
4th 180.2 ± 11.3a 405.7 ± 5.6b 112.1 ± 3.7a 344.2 ± 11.3b 122.4 ± 3.5a
8th 177.4 ± 9.5a 390.2 ± 3.8b, c 116.8 ± 3.2a 348.5 ±10.1b 120.6 ± 4.1a
12th 170.1 ± 10.9a 381.5 ± 4.2b, c 115.3 ± 3.9a 340.3 ± 8.1b 130.1 ± 4.5a
Values (mean ± SD) were obtained for each group of 8 animals. aP<0.05 and bP<0.01 compared to the values of vehicle-treated nondiabetic rats at the
corresponding time, respectively. cP<0.05 and dP<0.01 compared to the values of vehicle-treated STZ-diabetic rats at the corresponding time, respectively.
Table 2: Changes of the renal function-related parameters in STZ-diabetic rats receiving DSS treatment.
Groups Period
(week)
Serum Cr
(mgdL−1) BUN (mgdL−1) Urine volume
(mL−1)
Ccr
(mlmin−1 per kg) UAER (μg2 4h −1)
Nondiabetic rats
Vehicle
00 . 3 3 ± 0.09c 17.3 ± 2.6d 10.9 ± 2.8d 0.65 ± 0.15d 2.8 ± 0.2d
4th 0.34 ± 0.12c 17.8 ± 3.1d 11.4 ± 3.2d 0.62 ± 0.17d 2.6 ± 0.4d
8th 0.34 ± 0.09c 18.4 ± 2.8d 11.7 ± 2.9d 0.64 ± 0.14d 2.7 ± 0.2d
12th 0.35 ± 0.06c 18.2 ± 3.4d 12.1 ± 3.5d 0.68 ± 0.13d 2.9 ± 0.3d
STZ-diabetic rats
Vehicle
00 . 5 1 ± 0.06a 28.4 ± 3.3b 25.4 ± 3.7b 1.56 ± 0.21b 15.4 ± 2.1b
4th 0.53 ± 0.08a 29.7 ± 2.7b 26.9 ± 2.5b 1.64 ± 0.18b 16.3 ± 1.9b
8th 0.58 ± 0.07a 31.6 ± 3.6b 30.2 ± 2.8b 1.73 ± 0.15b 17.5 ± 2.6b
12th 0.64 ± 0.08a 33.6 ± 2.9b 33.6 ± 3.2b 1.80 ± 0.19b 19.4 ± 3.2b
DSS
(2.8gkg−1 per day)
00 . 5 0 ± 0.06a 28.6 ± 2.8b 25.3 ± 3.2b 1.55 ± 0.23b 14.9 ± 2.6b
4th 0.50 ± 0.10a 27.8 ± 3.2b 24.8 ± 3.4b 1.58 ± 0.16b 13.7 ± 2.5b
8th 0.51 ± 0.12a 28.2 ± 3.4b 26.2 ± 2.9b 1.52 ± 0.18b 14.8 ± 2.2b
12th 0.54 ± 0.09a 27.2 ± 3.5b 27.8 ± 2.8b 1.43 ± 0.21b 15.1 ± 3.1b
Values (mean ± SD) were obtained for each group of 8 animals. aP<0.05 and bP<0.01 compared to the values of vehicle-treated nondiabetic rats at the
corresponding time, respectively. cP<0.05 and dP<0.01 compared to the values of vehicle-treated STZ-diabetic rats at the corresponding time, respectively.
(Table 1). However, DSS made no inﬂuence on SBP in STZ-
diabetic rats during entire experiments (Table 1).
3.2. Changes in Renal Function-Related Parameters. During
the study period, levels of serum Cr and BUN in STZ-
diabetic rats were higher than those of nondiabetic group
(Table 2). At the termination of 12 weeks of DSS treatment,
the values for serum Cr and BUN of STZ-diabetic rats
were lower than those of their vehicle-treated counterparts
(Table 2). The urine volume in STZ-diabetic rats was
markedly (P<0.01) greater than that in nondiabetic rats
throughout the experimental period (Table 2). Lowering
urine volume in diabetic rats received DSS treatment was
exhibited at all time points throughout the experiments
(Table 2). Actually, the urine volume in DSS-treated STZ-
diabetic rats was still higher than the value from nondiabetic
rats at any time point throughout the study (Table 2).
T h el e v e l so fC c ra n dU A E Ri nd i a b e t i cr a t sw e r e
markedly (P<0.05) increased as compared with those for
nondiabetic rats; these values in STZ-diabetic rats were kept
increasing as relative to that in nondiabetic group at the
end of the study (Table 2). Treatment of STZ-diabetic rats6 Evidence-Based Complementary and Alternative Medicine
Table 3: Changes of the hypertrophy-related parameters in STZ-
diabetic rats receiving 12 weeks of DSS treatment.
Groups Kidney weight (g) Kidney weight/body
weight (mgg−1)
Nondiabetic rats
Vehicle 1.5 ± 0.2d 5.6 ± 0.4d
STZ-diabetic rats
Vehicle 2.9 ± 0.3b 16.5 ± 0.5b
DSS (2.8gkg−1 per
day) 2.1 ± 0.3b 12.3 ± 0.2b, c
Values (mean ± SD) were obtained for each group of 7 animals. bP<0.01
compared to the values of vehicle-treated nondiabetic rats. cP<0.05 and
dP<0.01 compared to the values of vehicle-treated STZ-diabetic rats,
respectively.
with DSS resulted in a partial reversal of these abnormal
parameters, and the eﬀects of DSS were persisted at the end
of 12-week treatment (Table 2).
3.3. Inﬂuences on the Kidney Hypertrophy. At the end of
study period, the mean kidney weight and the ratio of
kidneyweighttobodyweightinvehicle-treatedSTZ-diabetic
were signiﬁcantly increased as compared to those in the
nondiabetic group (P<0.01, Table 3). Treatment STZ-
diabeticratswith12weeksofDSSreducedthedegreeofrenal
hypertrophy (Table 3).
3.4. Inﬂuence on the Renal Histology. Mesangial matrix
fraction of glomeruli observed in PAS-stained images has
been shown in Figure 1(a). Although the eﬀect induced by
DSS was not achieved to that from normal rats, mesangial
matrix fraction in diabetic rats received a 12-week treatment
with DSS was lower than that of their vehicle-treated
counterparts. The index of the glomerular matrix expansion
in each study group was shown in Figure 1(b).
3.5. Inﬂuence on the Renal Expression of NF-κB, TGF-
β1,a n dT y p eI VC o l l a g e n .Renal immunostaining for NF-
κB expression in STZ-diabetic rats receiving 12 weeks of
DSS (2.8gkg−1 per day) treatment has been indicated in
Figure 2(a). Semi-quantitative assessment of the immunos-
taining for the protein indicating that the NF-κB expression
in vehicle-treated STZ-diabetic rats was markedly higher
than that of vehicle-treated nondiabetic rats (Figure 2(b)).
The elevated NF-κB protein expressions in kidney of STZ-
diabetic rats were reduced by 12 weeks of DSS treatment
(Figure 2(a)). The STZ-diabetic rats exhibited greater TGF-
β1 immunostaining in glomeruli; treatment with DSS at the
12th week showed reduced TGF-β1 p r o t e i ni ng l o m e r u l i
(Figure 2). The type IV collagen was accumulated in the
glomeruli of STZ-diabetic rats relative to that of nondiabetic
group. After 12 weeks of experimental period, the extents of
typeIVcollagenexpressioninglomeruliofDSS-treatedSTZ-
diabeticratswereclearlylessthanthatoftheirvehicle-treated
counterparts (Figure 2).
3.6.InﬂuenceontheRenalAGEs,CML,andLipidPeroxidation
Products. Both the higher renal levels of AGEs and CML
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Figure 1: (a) Representative photomicrographs (original magni-
ﬁcation, 200x) of PAS-stained kidney sections from STZ-diabetic
rats receiving 12 weeks of DSS (2.8g/kg/day) treatment. The vehicle
(distilled water) used to disperse DSS was given at the same volume.
(b) Expansion of the glomerular matrix was scored using 4 levels,
and an average value was obtained from analyses of more than 30
glomeruliperrat.Values(mean ±SD)wereobtainedforeachgroup
of 4 animals. bP<0.01 compared to the values of vehicle-treated
nondiabetic rats. cP<0.05 and dP<0.01 compared to the values of
vehicle-treated STZ-diabetic rats, respectively.
in vehicle-treated STZ-diabetic rats were eﬀectively lowered
by 12 weeks of 2.8gkg−1 per day DSS treatment (Table 4).
Meanwhile, the lipid peroxidation products level was sig-
niﬁcantly elevated in STZ-diabetic rats. At the termination
of 12— weeks of DSS treatment, the increased renal lipid
peroxidation products in STZ-diabetic rats were signiﬁcantly
reduced as relative to their vehicle-treated counterparts
(Table 4).
3.7. Changes on Antioxidant Enzyme Activity in Renal Cortex.
Although signiﬁcant decrease in SOD and GSH-Px activity
in kidney was found in STZ-diabetic rats as compared with
those of the nondiabetic group, both the activities of SOD
andGSH-PxinkidneyofDSS-treatedSTZ-diabeticratswere
signiﬁcantly higher than values in vehicle-treated group at
the end of the 12-week treatment (Table 4).
4. Discussion
Diabetic nephropathy is a progressive disease that causes
glomerular ﬁbrosis and impairment of renal function, withEvidence-Based Complementary and Alternative Medicine 7
Table 4: Renal levels of AGEs, CML, lipid peroxidation products, and antioxidant enzyme activity in STZ-diabetic rats receiving 12 weeks
of DSS treatment.
Groups AGEs (AU) CML (ngmg−1) Lipid peroxidation products (nmolmg−1) SOD (Umg−1) GSH-Px
(Umg−1)
Nondiabetic rats
Vehicle 3.1 ± 0.2d 20.2 ± 4.3d 6.4 ± 0.6d 12.3 ± 0.8d 2.8 ± 0.4c
STZ-diabetic rats
Vehicle 6.8 ± 0.3b 43.3 ± 5.6b 14.8 ± 1.2b 6.7 ± 0.6b 1.5 ± 0.2a
DSS (2.8gkg−1 per day) 4.3 ± 0.2a, c 30.4 ± 3.7a, c 10.3 ± 0.7a, c 10.1 ± 0.5a, c 2.3 ± 0.2 c
Values (mean ± SD) were obtained for each group of 7 animals. aP<0.05 and bP<0.01 compared to the values of vehicle-treated nondiabetic rats,
respectively. cP<0.05 and dP<0.01 compared to the values of vehicle-treated STZ-diabetic rats, respectively.
progression over time. Urinary albumin excretion has been
demonstrated to be a good clinical predictor of renal
lesions in diabetic nephropathy [22, 23]. Increase in urinary
albumin concentration corresponding to the hyperglycemia
was observed in rats following diabetes induction. Further-
more, serum levels of creatinine and urea nitrogen as well
as creatinine clearance, which are generally considered as
markers of renal function, were higher in STZ-diabetic rats
than those of nondiabetic group, implying the presence
of diabetic kidney disease with renal hyperﬁltration. We
observed that repeated treatment with DSS could attenuate
albuminuria as well as ameliorate the loss of renal function
and glomerular hyperﬁltration in STZ-diabetic rats. In
addition to the increase in urinary albumin excretion, one of
the most remarkable renal pathological ﬁndings in diabetic
nephropathy is mesangial expansion due to pathological
accumulation of extracellular matrix (ECM) components
in glomeruli [24]. Considering that type IV collagen is the
major constituent in the basement membranes of kidney
[25], immunohistological staining of type IV collagen in
glomeruli was performed to further clarify the eﬀect of
DSS on glomerular ﬁbrosis. In our experimental diabetic
rat model, type IV collagen was strikingly accumulated in
the mesangial area of glomeruli but was expressed at lower
levels in glomeruli of STZ-diabetic rats treated with 12 weeks
of DSS. Furthermore, the accelerated mesangial expansion
in glomeruli of STZ-diabetic rats was remissive after DSS
treatment. The renal histological analysis reﬂected that this
prescriptionhaspotentialeﬀectsonthedeteriorationofrenal
ﬁbrosis through reduction of renal ECM accumulation in
STZ-diabetic rats.
Much attention has been focused on exploring mecha-
nisms related to the development of diabetic nephropathy.
At present, several growth factors have been proposed to
be involved in mediating the development of diabetic renal
hypertrophy; among them, the multifunctional cytokine
TGF-β1 is known to be upregulated in diabetic kidney [26].
TGF-β1 is believed to contribute to a prominent role in the
mesangial cell proliferation and ECM production, the major
pathological changes in early diabetic nephropathy [26].
Thus, TGF-β1 has been considered as a therapeutic target
in ﬁbrotic disease such as diabetic nephropathy and other
chronic kidney diseases [27]. It was worth noting that the
overexpression of TGF-β1 in glomeruli of diabetic rats was
lessenedfollowingtheloweringofplasmaglucoseunderlying
DSS treatment. The plasma glucose lowering eﬀect induced
by treatment of diabetic rats with DSS represents an obvious
factor in the assessment of the mechanism(s) by which this
formula may have prevented renal functional and structural
changes in the diabetic rats.
It has long been known that hypertension is an aggravat-
ing factor in increased intraglomerular pressure and may be
the key hemodynamic determinant of diabetic renal injury
as well; it is therefore well recognized that blood pressure
control is important in diabetic patients [5]. Actually, DSS
was observed to make less inﬂuence on the blood pressure
in STZ-diabetic rats throughout the study period. These data
have implications that DSS exhibits a renoprotective eﬀect in
an animal model of diabetic nephropathy by inhibiting the
expression of TGF-β1, which might be linked to its beneﬁcial
eﬀect on the hyperglycemic state but did not correlate with
blocking intrarenal renin angiotensin system.
The hyperglycemia condition, a chronic metabolic dis-
order of glucose, results in irreversible tissue damage by the
protein glycation reaction, which leads to the formations
of glycosylated protein and AGEs [2]. It has been reported
that AGEs trigger the activation of NF-κB by interaction
with receptor for AGE (RAGE), leading to its translocation
to the nucleus where it induces transcription, and the
promoter region of the RAGE gene contains NF-κB binding
sites, potentially producing a self-perpetuating pathway.
Moreover, the AGE-RAGE interaction activates TGF-β1
signaling pathways and subsequently induces mesangial cell
hypertrophy and glomerular sclerosis by ECM synthesis
[2]. Therefore, AGEs accumulation in the kidney has been
regarded as an index of progressive renal damage in diabetic
nephropathy. Actually, not only the overexpression of AGEs
but also the higher levels of NF-κBa n dT G F - β1 in kidney of
STZ-diabetic rats were alleviated by 12 weeks of 2.8gkg−1
per day DSS treatment. It seems that DSS inﬂuenced not
only the AGE-RAGE signaling but also the NF-κB-TGF-β1-
dependent pathway to some extent, thus leading to attenuate
renal damage caused by the protein glycation reaction.
When considering AGEs from another viewpoint, CML,
pentosidine, and methylglyoxal derivatives are among some
of the well-characterized compounds that commonly are
used as AGE markers [28]. Particularly, CML is not only
referred to as a glycoxidation product, but is also formed
during the metal-catalyzed oxidation of polyunsaturated
fatty acids in the presence of protein [29]. Therefore,8 Evidence-Based Complementary and Alternative Medicine
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Figure 2: (a) Renal immunostaining for NF-κB, TGF-β1,a n dt y p e
IV collagen expression in STZ-diabetic rats receiving 12 weeks
of DSS (2.8gkg−1 per day) treatment. Original magniﬁcation,
200x. The vehicle (distilled water) used to disperse DSS was
given at the same volume. (b) Semiquantitative assessments of the
immunostaining for proteins were scored using 4 levels, and an
averagevaluewasobtainedfromanalysesofmorethan30glomeruli
per rat. Values (mean ± SD) were obtained for each group of
4 animals. bP<0.01 compared to the values of vehicle-treated
nondiabetic rats, respectively. cP<0.05 and dP<0.01 compared
to the values of vehicle-treated STZ-diabetic rats, respectively.
CML could serve as a general biomarker of oxidative stress
resulting from carbohydrate and lipid oxidation reactions.
We found that treatment of diabetes with 12 weeks of DSS
not only lowered the renal CML level but also decreased the
accumulation of lipid peroxidation products in kidney. The
results indicated that the beneﬁcial eﬀect of DSS on diabetic
nephropathy was linked to reduce the intensity of oxidative
stress.
Diabetes exhibits high oxidative stress due to persistent
and chronic hyperglycemia, which thereby depletes the
activityofantioxidativedefensesystemandthuspromotesde
novo free radicals generation; strategies to reduce oxidative
stress in diabetes mellitus may exert favorable eﬀects on
the progression of diabetic glomerulosclerosis [30, 31].
Among antioxidative enzymes, SOD catalyzes dismutation
of the superoxide anion into hydrogen peroxide, while
GSH-Px both detoxiﬁes hydrogen peroxides and converts
lipid hydroperoxides to nontoxic alcohols; thus, antioxidant
enzymes activities could reﬂect antioxidant defense status
[32]. In this work, the reduced activities of SOD and GSH-
Px in kidney of STZ-diabetic rats were elevated by DSS.
The classical formula protecting kidney of diabetic rats from
oxidative damage by enhancing enzymatic antioxidative
defense systems could be considerable.
Theﬁndingsofthepresentstudyareofmeritinrevealing,
for the ﬁrst time, that DSS has an antidiabetic property with
plasma glucose lowering action to reduce hyperglycemia-
induced generation reactive oxygen species. DSS also, with
the capacity to ameliorate the defective antioxidative defense
system, leads to modulate the oxidative stress, thereby
resulting in downregulation of NF-κBa sw e l la sT G F - β1 and
consequently attenuation of type IV collagen expression in
diabetic renal cortex tissue. Although DSS did not produce
statistically signiﬁcant eﬀect on the amelioration of diabetic-
dependentalterationsinurinaryalbumin,albuminexcretion
rate, and creatinine clearance, this classical formula can
prevent or retard the development of diabetic nephropathy
via its beneﬁcial eﬀects for correcting the hyperglycemia,
antioxidantenzymesystem,renaldysfunctionandprotecting
against histopathological changes in the kidneys of diabetic
rats which cannot be neglected. The Chinese prescription
may therefore possess utility as adjuvant therapy for control
of diabetes and its complications.
Free radicals play vital role in the inﬂammation, demen-
tia as well as diabetic nephropathy, and the other diseases
[33].Traditionally,DSSwasusedtorelievemenorrhalgiaand
other abdominal pains of women [12, 13]. The therapeutic
eﬀect of DSS on Alzheimer’s disease was also reported
[14, 15]. Beneﬁcial eﬀect of DSS on AGEs-mediated renal
injury in diabetic rats has been clariﬁed in the present study.
ThepotentialrelationshipsamongtheseDSS-treateddiseases
might be related to the capacity of this prescription on
reducing oxidative stress under diseases.
Most TCM remedies are formulated to contain diﬀerent
herbs in combination in order to enhance the curative
eﬃcacy and also reduce the side eﬀects. Monoterpene
glycosides, phenolic compounds, and phthalides are the
most representative components of DSS as far as both the
contents and their biological activities are concerned [6–11].
Further studies will be required to identify the major active
constituentsinDSSthatisresponsibleforthebeneﬁcialrenal
eﬀects observed in the present study.
In conclusion, DSS showed an antidiabetic eﬀect via
reducing hyperglycemia to attenuate AGEs expression and
downregulate NF-κB-TGF-β1 pathway in diabetic glomeruli,
consequently lessening ECM deposition in renal tissue.
Besides, the oxygen radical scavenging properties of DSS for
amelioration of diabetic nephropathy cannot be excluded.Evidence-Based Complementary and Alternative Medicine 9
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